The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed at $2.67 in the last session, up 6.37% from day before closing price of $2.51. In other words, the price has increased by $6.37 from its previous closing price. On the day, 1.92 million shares were traded. XERS stock price reached its highest trading level at $2.7455 during the session, while it also had its lowest trading level at $2.51.
Ratios:
We take a closer look at XERS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.
On October 21, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $4.Jefferies initiated its Buy rating on October 21, 2022, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 12 ’24 when Schmid John P. bought 4,515 shares for $2.25 per share. The transaction valued at 10,147 led to the insider holds 25,200 shares of the business.
Schmid John P. bought 4,285 shares of XERS for $10,134 on Aug 09 ’24. The Director now owns 20,685 shares after completing the transaction at $2.37 per share. On May 10 ’24, another insider, Schmid John P., who serves as the Director of the company, bought 5,400 shares for $1.91 each. As a result, the insider paid 10,314 and bolstered with 16,400 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 397827360 and an Enterprise Value of 590062848. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19. Its current Enterprise Value per Revenue stands at 3.253 whereas that against EBITDA is -23.603.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $3.26, while it has fallen to a 52-week low of $1.46. The 50-Day Moving Average of the stock is 8.20%, while the 200-Day Moving Average is calculated to be 16.25%.
Shares Statistics:
According to the various share statistics, XERS traded on average about 1.41M shares per day over the past 3-months and 1655610 shares per day over the past 10 days. A total of 138.13M shares are outstanding, with a floating share count of 136.40M. Insiders hold about 8.46% of the company’s shares, while institutions hold 38.15% stake in the company. Shares short for XERS as of 1723680000 were 10809571 with a Short Ratio of 7.69, compared to 1721001600 on 11410828. Therefore, it implies a Short% of Shares Outstanding of 10809571 and a Short% of Float of 7.430000000000001.
